首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Journal Of Hematology & Oncology

Journal Of Hematology & Oncology杂志,由BioMed Central出版,于2008年创刊,Irregular,出版语言English,ISSN:1756-8722,E-ISSN:1756-8722。

投稿咨询
Journal Of Hematology & Oncology
Journal Of Hematology & Oncology
Journal Of Hematology & Oncology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
47.8
CiteScore
70.1
期刊收录
SCI、SCIE

Journal Of Hematology & Oncology(中文译名:《血液学与肿瘤学杂志》),ISSN:1756-8722,EISSN:1756-8722,是BioMed Central出版的国际性学术期刊,创刊于2008年,以Irregular形式稳定发行,2026年总发文量约75篇。该刊采用OA开放访问,学科归属为医学 - 血液学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达47.8,2025年期刊CiteScore为70.1,2025年期刊自引率约1%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Journal Of Hematology & Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期较慢,6-12周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDUSA、Italy、France、GERMANY (FED REP GER)、Spain、Canada等为核心发文国家与地区;ZHENGZHOU UNIVERSITYFUDAN UNIVERSITY、UNIVERSITY OF TEXAS SYSTEM、PEKING UNIVERSITY、CHINESE ACADEMY OF MEDICAL SCIENCES - PEKING UNION MEDICAL COLLEGE、ZHEJIANG UNIVERSITY、HUAZHONG UNIVERSITY OF SCIENCE & TECHNOLOGY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学 HEMATOLOGY 血液学
1区 1区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
1区 1区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
1区 1区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 1 / 103

99.5

学科:ONCOLOGY SCIE Q1 6 / 333

98.3

学科:HEMATOLOGY SCIE Q1 1 / 103

99.51

学科:ONCOLOGY SCIE Q1 9 / 333

97.45

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 1 / 99

99.5

学科:ONCOLOGY SCIE Q1 7 / 328

98

学科:HEMATOLOGY SCIE Q1 1 / 100

99.5

学科:ONCOLOGY SCIE Q1 10 / 328

97.1


中国学者近期发文

1
CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meetin

Author:Geng, Chuanying; Chen, Wenming; Zhu, Hong-Hu

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1186/s13045-026-01793-8

2
Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participant

Author:Lin, Pao-Yen; Zeng, Bing-Syuan; Chen, Jiann-Jy; Zeng, Bing-Yan; Suen, Mein-Woei; Hung, Chao-Ming; Hsu, Chih-Wei; Stubbs, Brendon; Chen, Yen-Wen; Chen, Tien-Yu; Lei, Wei-Te; Hsu, Shih-Pin; Shiue, Yow-Ling; Su, Kuan-Pin; Li, Cheng-Ta; Wang, Hung-Yu; Tseng, Ping-Tao; Liang, Chih-Sung

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1186/s13045-026-01788-5

3
In vivo CAR-T cell therapy: latest updates from 2025 ASH annual meetin

Author:Gao, Pan; Liu, Jun; Ma, Jun; Ma, Hengrui; Zhang, Ya

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1186/s13045-026-01787-6

4
Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase 3 tria

Author:Wu, Runhui; Gao, Ju; Liu, Yufeng; Yu, Jie; Hu, Shaoyan; Liang, Hui; Jiang, Hui; Zhai, Xiaowen; Zhou, Min; Hao, Wenge; Mei, Heng; Li, Fei; Chen, Yumei; Liu, Wei; Yan, Mei; Li, Runzi; Xiong, Junye; Zhu, Zhenyi; Cheng, Xiaoling; Wang, Tianyou

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1186/s13045-026-01790-x

5
CXCR4-antagonistic peptide-decorated lipid nanoparticles for co- delivery of AML1-ETO siRNA to enhance chemotherapy in refractory AM

Author:Peng, Xuelu; Gu, Runxia; Wang, Tao; Jiang, Chuanmei; Xing, Haiyan; Meng, Jie; Wen, Tao; Liu, Jian; Wang, Jianxiang; Xu, Haiyan

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1186/s13045-026-01785-8

6
IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorder

Author:Wu, Youqian; Zhang, Ruiqi; Sun, Beibei; Chen, Gaoying; Xu, Fang; Chen, Xinyi; Zeng, Jiayuan; Shen, Dan; Shi, Fan; Pan, Sheng; Yao, Bingpeng; Tang, Haoyu; Shao, Zhehua; Wu, Qian; Shao, Jiawei; Zhang, Chao; Wang, Dongrui; Hu, Yongxian; Ying, Songmin

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1186/s13045-026-01782-x

7
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic application

Author:Li, Jiayi; Huang, Chen; Tang, Pan; Wu, Ruiyan; Wu, Quanyou; Zhang, Chenliang

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1186/s13045-026-01780-z

8
CBX3 confers ferroptosis resistance during blood-borne metastasi

Author:Wu, Chun; Liu, Xuefei; Zhao, Boxi; Zhao, Mao; Zhang, Binyu; Huang, Guanyin; Cheng, Yixin; Zheng, Shuqian; Hu, Jianyang; Guo, Ling; Guo, Weinan; Tan, Jun; Hong, Xin

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2026; Vol. 19, Issue 1, pp. -. DOI: 10.1186/s13045-025-01777-0

9
Deciphering cholangiocarcinoma heterogeneity and specific progenitor cell niche of extrahepatic cholangiocarcinoma at single-cell resolutio

Author:Liu, Chunliang; Wang, Xiang; Liu, Erdong; Zong, Yali; Yu, Wenlong; Jiang, Youhai; Chen, Jianan; Gu, Mingye; Meng, Zhengyuan; Li, Jingfeng; Liu, Yang; Zhang, Yongjie; Tang, Jing; Wang, Hongyang; Fu, Jing

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2025; Vol. 18, Issue 1, pp. -. DOI: 10.1186/s13045-025-01716-z

10
Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherap

Author:Hu, Qin; Zhu, Yifei; Mei, Jie; Liu, Ying; Zhou, Guoren

Journal: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2025; Vol. 18, Issue 1, pp. -. DOI: 10.1186/s13045-025-01717-y


在线咨询

Journal Of Hematology & Oncology

国际简称:J HEMATOL ONCOL参考译名:血液学与肿瘤学杂志

年发文量:75 CiteScore:70.1 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:45.33%

杂志社联系方式:BIOMED CENTRAL LTD, 236 GRAYS INN RD, FLOOR 6, LONDON, ENGLAND, WC1X 8HL

Journal Of Hematology & Oncology